How Does SS-31 Interact with Cardiolipin?

SS-31 (elamipretide) is one of the most widely studied mitochondria-targeted peptides in experimental biology. Unlike classic free-radical scavengers, its activity is proposed to arise primarily from structural interaction with the inner mitochondrial membrane and cardiolipin, alongside direct reactive oxygen species (ROS)-scavenging properties that have also been investigated.

This article explains the proposed mechanisms of SS-31, its interaction with cardiolipin, effects on membrane organization and bioenergetics, and the current state of the evidence across preclinical and clinical research.

Cardiolipin is a distinctive phospholipid enriched in the inner mitochondrial membrane. Its abundance varies by tissue, cell type and physiological condition, and it plays an important role in mitochondrial membrane organization and respiratory-chain function.

Its functional roles include:

• Supports cristae architecture and mitochondrial membrane organization
• Helps organize respiratory-chain complexes and supercomplexes
• Contributes to efficient electron transport and oxidative phosphorylation
• Participates in the structural and functional organization of mitochondrial membrane proteins

Under conditions of oxidative stress, aging and disease, cardiolipin can become peroxidized and depleted. This may disrupt cristae structure, destabilize respiratory complexes and reduce bioenergetic efficiency.

The proposed mechanism of SS-31 centers on electrostatic and hydrophobic interactions with cardiolipin-containing membranes.

SS-31 is a member of the Szeto–Schiller (SS) peptide family. It carries positively charged arginine and lysine residues alongside the aromatic residues Dmt (2,6-dimethyltyrosine) and phenylalanine. Studies suggest this structure drives two key behaviors:

• Membrane interaction - The aromatic and hydrophobic residues support interaction with the hydrophobic core of the inner mitochondrial membrane, where the peptide is proposed to bind negatively charged cardiolipin headgroups through electrostatic contacts.
• Cardiolipin affinity - Experimental studies indicate that SS-31 interacts with cardiolipin in a way that may stabilize membrane structure, reduce the susceptibility of cardiolipin to peroxidation, and help preserve the organization of respiratory chain complexes.

Unlike conventional mitochondria-targeting compounds whose uptake is strongly dependent on mitochondrial membrane potential, SS-31 accumulation cannot be explained solely by electrophoretic attraction. Its membrane affinity and molecular structure are important parts of the proposed targeting mechanism.

SS-31 has been investigated for both reactive oxygen species (ROS)-scavenging activity and cardiolipin-associated effects on mitochondrial membrane organization. Experimental evidence supports these as relevant mechanisms, but their relative contributions to the observed biological effects are not fully resolved. The extent to which these mechanisms explain outcomes across different tissues, disease models and clinical indications remains an important research question.

By stabilizing cardiolipin-containing domains, SS-31 is proposed to support the structural integrity of inner membrane cristae.

Under stress conditions that would otherwise promote cardiolipin peroxidation, membrane remodeling and cristae disruption, studies suggest SS-31 may help preserve membrane architecture. This structural preservation is thought to underlie many of the peptide's reported cytoprotective effects in experimental models.

At the functional level, SS-31 is proposed to influence multiple aspects of mitochondrial bioenergetics:

• Respiratory chain efficiency - By supporting complex and supercomplex organization, SS-31 may improve electron transport efficiency and reduce electron leak from the respiratory chain.
• ATP production - Improved respiratory efficiency may help maintain ATP production under stress conditions.
• Reactive oxygen species - Reduced electron leak may lower mitochondrial ROS production at the source, in addition to any direct ROS-scavenging activity.
• Calcium handling - Some studies also report effects on mitochondrial calcium handling and permeability transition pore regulation.

These effects are best supported under stressed conditions; improvements in resting healthy tissue are generally less pronounced in experimental studies.

Evidence strength varies by study type:

• Biophysical and model membrane studies provide the strongest support for the cardiolipin interaction and membrane stabilization model.
• Cell culture studies have investigated improved mitochondrial respiration, reduced ROS and increased resistance to stress-induced cell death across multiple cell types.
• Animal disease models have reported beneficial effects in cardiac ischemia-reperfusion, skeletal muscle myopathy, renal injury, neurodegeneration and retinal disease models.

Effects are typically more robust under stress conditions than in healthy resting tissue, and magnitude varies by dose, route, timing and model.

Clinical development of elamipretide has advanced for specific indications:

• Barth syndrome - On September 19, 2025, the U.S. FDA granted accelerated approval to Forzinity™ (elamipretide injection) for improving muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. Approval was based on knee extensor muscle strength as an intermediate endpoint, and post-marketing confirmatory studies may be required to verify clinical benefit.
• Other indications - Clinical results have not been uniformly positive. In the phase 3 MMPOWER-3 trial in primary mitochondrial myopathy, elamipretide did not meet its primary endpoints for six-minute walk distance or total fatigue at 24 weeks.

The FDA approval applies to Forzinity, a specific elamipretide injection product for the labeled Barth syndrome indication. It should not be interpreted as approval of research-grade SS-31 peptide powder, other formulations, or other disease indications.

Key open questions remain:

• The exact molecular mechanism and binding partners continue to be refined.
• Translation from preclinical efficacy to human clinical benefit remains inconsistent across indications.
• Optimal dosing, delivery and timing for different applications remain active areas of investigation.
• Long-term safety data across all populations remain limited.

What is the relationship between SS-31 and cardiolipin?

SS-31 is proposed to interact with cardiolipin in the inner mitochondrial membrane through electrostatic and hydrophobic contacts, helping to stabilize membrane structure and support respiratory chain organization. This interaction is thought to underpin many of its reported bioenergetic effects.

Does SS-31 affect mitochondrial bioenergetics?

Studies suggest SS-31 may influence mitochondrial bioenergetics by supporting respiratory chain organization and reducing electron leak. Effects may include improved ATP production and reduced ROS production under stress conditions.

Is SS-31 the same as elamipretide?

Yes. SS-31 is the common research code name; elamipretide is the international nonproprietary name (INN) for the same active moiety. MTP-131 and Bendavia are additional designations in the literature.

Are preclinical findings sufficient to establish clinical efficacy?

No. Preclinical results provide rationale and supporting evidence for clinical investigation, but they do not guarantee human efficacy. Clinical outcomes must be evaluated for each indication separately.

The proposed cardiolipin-targeted membrane-stabilizing mechanism, together with investigated ROS-scavenging activity, provides a framework for understanding SS-31's preclinical effects. While biophysical and cellular evidence is strong, clinical translation remains variable and indication-specific, as demonstrated by both the Barth syndrome approval and the negative MMPOWER-3 myopathy trial.

For a basic introduction to the peptide and its molecular identity, see our article on what SS-31 peptide is. For an overview of the broader research landscape, see our SS-31 peptide research update.

For product specifications and sourcing information, visit the SS-31 Peptide Powder product page.

Szeto H.H. (2014). Mitochondria-targeted peptides: Pharmacophore development and therapeutic applications. Acc Chem Res. 47(7):2015-2023. 

Sparvero L., et al. (2026). Cardiolipin remodelling in mitochondrial therapeutics: translational evidence chains from elamipretide to emerging strategies. Front Physiol. 17:1813119. 

Karaa A., et al. (2024). Elamipretide in primary mitochondrial myopathy: the MMPOWER-3 phase 3 randomized controlled trial. Neurology. 

U.S. Food and Drug Administration. Forzinity (elamipretide) injection - prescribing information. September 2025. 

PubChem. Elamipretide. CID 11764719.